19-1218460-C-G
Variant summary
Our verdict is Uncertain significance. The variant received 4 ACMG points: 4P and 0B. PM1PM2
The NM_000455.5(STK11):c.334C>G(p.Gln112Glu) variant causes a missense change. The variant allele was found at a frequency of 0.00000137 in 1,461,338 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q112H) has been classified as Uncertain significance.
Frequency
Consequence
NM_000455.5 missense
Scores
Clinical Significance
Conservation
Publications
- familial pancreatic carcinomaInheritance: AD Classification: DEFINITIVE Submitted by: G2P
- Peutz-Jeghers syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Orphanet, Genomics England PanelApp, G2P
- familial ovarian cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
STK11 | NM_000455.5 | c.334C>G | p.Gln112Glu | missense_variant | Exon 2 of 10 | ENST00000326873.12 | NP_000446.1 | |
STK11 | NM_001407255.1 | c.334C>G | p.Gln112Glu | missense_variant | Exon 2 of 9 | NP_001394184.1 | ||
STK11 | NR_176325.1 | n.1601C>G | non_coding_transcript_exon_variant | Exon 3 of 11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
STK11 | ENST00000326873.12 | c.334C>G | p.Gln112Glu | missense_variant | Exon 2 of 10 | 1 | NM_000455.5 | ENSP00000324856.6 | ||
STK11 | ENST00000652231.1 | c.334C>G | p.Gln112Glu | missense_variant | Exon 2 of 9 | ENSP00000498804.1 | ||||
STK11 | ENST00000593219.6 | n.*159C>G | non_coding_transcript_exon_variant | Exon 3 of 11 | 3 | ENSP00000466610.1 | ||||
STK11 | ENST00000585748.3 | c.-39C>G | 5_prime_UTR_variant | Exon 4 of 12 | 3 | ENSP00000477641.2 | ||||
STK11 | ENST00000593219.6 | n.*159C>G | 3_prime_UTR_variant | Exon 3 of 11 | 3 | ENSP00000466610.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD2 exomes AF: 0.00000803 AC: 2AN: 249176 AF XY: 0.0000148 show subpopulations
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461338Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 726920 show subpopulations
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Peutz-Jeghers syndrome Uncertain:3
This missense variant replaces glutamine with glutamic acid at codon 112 of the STK11 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Functional studies have shown that the mutant protein retained autophosphorylation activity in an in vitro kinase assay (PMID: 34849607). This variant has been reported in an individual affected with advanced cancer (PMID: 28873162). This variant has been identified in 2/249176 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 112 of the STK11 protein (p.Gln112Glu). This variant is present in population databases (rs771049807, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with STK11-related conditions. ClinVar contains an entry for this variant (Variation ID: 185602). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt STK11 protein function with a negative predictive value of 95%. Experimental studies have shown that this missense change does not substantially affect STK11 function (PMID: 34849607). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
Hereditary cancer-predisposing syndrome Uncertain:3
- -
The p.Q112E variant (also known as c.334C>G), located in coding exon 2 of the STK11 gene, results from a C to G substitution at nucleotide position 334. The glutamine at codon 112 is replaced by glutamic acid, an amino acid with highly similar properties. Based on protein sequence alignment, this amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
This missense variant replaces glutamine with glutamic acid at codon 112 of the STK11 protein. Computational prediction suggests that this variant may not impact protein structure and function. Functional studies have shown that the mutant protein retained autophosphorylation activity in an in vitro kinase assay (PMID: 34849607). This variant has been reported in an individual affected with advanced cancer (PMID: 28873162). This variant has been identified in 2/249176 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at